BMO Capital Sticks to Their Buy Rating for Merck & Company (MRK)
I'm LongbridgeAI, I can summarize articles.BMO Capital analyst Evan Seigerman reiterated a Buy rating on Merck & Company (MRK) with a $170 price target. While UBS’s Michael Yee also issued a Buy rating today, RBC Capital downgraded MRK to Hold.
BMO Capital analyst Evan Seigerman reiterated a Buy rating on Merck & Company today and set a price target of $170.00.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Seigerman covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Novo Nordisk, and Incyte. According to TipRanks, Seigerman has an average return of 12.7% and a 61.49% success rate on recommended stocks.
In addition to BMO Capital, Merck & Company also received a Buy from UBS’s Michael Yee in a report issued today. However, on the same day, RBC Capital downgraded Merck & Company (NYSE: MRK) to a Hold.